Tag #Blood Tests

Showing 1 to 4 of 4 results

bbc.com

🌐 85% Global Worthiness

Sep 5, 04:17

55,000 Diabetes Patients Need Retesting Due to Machine Errors

In England, faulty diabetes testing machines have resulted in at least 55,000 patients requiring retests, with some wrongly diagnosed and medicated; the issue stems from 16 hospital trusts using Trinity Biotech machines, first flagged in April 2024.

55,000 Diabetes Patients Need Retesting Due to Machine Errors

In England, faulty diabetes testing machines have resulted in at least 55,000 patients requiring retests, with some wrongly diagnosed and medicated; the issue stems from 16 hospital trusts using Trinity Biotech machines, first flagged in April 2024.

Progress

16% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What is the immediate impact of the faulty diabetes testing machines on patients?

At least 55,000 individuals in England require additional blood tests due to inaccurate results from faulty machines. Some patients received incorrect type 2 diabetes diagnoses and unnecessary medication, causing stress and health issues, as illustrated by Vicky Davies's experience with Metformin.

bbc.com

🌐 85% Global Worthiness

Dec 20, 04:10

AI Blood Tests Show Promise in Early Ovarian Cancer Detection

New AI-powered blood tests are showing promise in detecting ovarian cancer five years before symptoms appear, improving diagnosis and survival rates; AI also speeds up pneumonia diagnosis and antibiotic selection, reducing costs and improving patient care.

AI Blood Tests Show Promise in Early Ovarian Cancer Detection

New AI-powered blood tests are showing promise in detecting ovarian cancer five years before symptoms appear, improving diagnosis and survival rates; AI also speeds up pneumonia diagnosis and antibiotic selection, reducing costs and improving patient care.

Progress

44% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

How are AI-powered blood tests revolutionizing early ovarian cancer detection and improving patient outcomes?

AI-powered blood tests are emerging for early ovarian cancer detection, potentially reducing mortality by enabling diagnosis five years before symptoms appear. These tests analyze blood samples using nanotubes and AI to identify subtle molecular patterns indicative of cancer, surpassing the accuracy of existing biomarkers.

dailymail.co.uk

🌐 85% Global Worthiness

Apr 15, 13:16

Inaccurate Blood Tests from Synnovis Cause NHS Chaos

A London-based blood testing company, Synnovis, which provides services to nearly 200 GP surgeries and six hospitals, has been issuing inaccurate blood test results since 2021, causing patient distress, unnecessary hospital referrals, and wasted appointments; this follows a major cyberattack in 2022...

Inaccurate Blood Tests from Synnovis Cause NHS Chaos

A London-based blood testing company, Synnovis, which provides services to nearly 200 GP surgeries and six hospitals, has been issuing inaccurate blood test results since 2021, causing patient distress, unnecessary hospital referrals, and wasted appointments; this follows a major cyberattack in 2022...

Progress

48% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

How did the previous cyberattack on Synnovis compound the current problems with inaccurate test results?

Synnovis, a £2 billion NHS blood analyst, has admitted to repeated inaccuracies since 2021, eroding trust among medical professionals. This follows a 2022 cyberattack that exposed patient data and disrupted services, leading to thousands of cancelled appointments and procedures. The scale of the issue, described as a 'national scandal' by some GPs, raises serious concerns about healthcare system reliability.

smh.com.au

🌐 85% Global Worthiness

Dec 16, 07:09

Proteomics International Secures \$2.16 Million R&D Rebate for Diagnostic Blood Tests

Proteomics International secured a \$2.16 million Australian R&D tax rebate to commercialize its innovative blood tests for diabetic kidney disease, endometriosis, and esophageal cancer, leveraging a \$4.95 million R&D investment and aiming for US market entry.

Proteomics International Secures \$2.16 Million R&D Rebate for Diagnostic Blood Tests

Proteomics International secured a \$2.16 million Australian R&D tax rebate to commercialize its innovative blood tests for diabetic kidney disease, endometriosis, and esophageal cancer, leveraging a \$4.95 million R&D investment and aiming for US market entry.

Progress

40% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What is the immediate impact of the \$2.16 million R&D tax rebate on Proteomics International and the Australian healthcare landscape?

Proteomics International received a \$2.16 million R&D tax rebate from the Australian government. This funding will support the commercial launch of its novel blood tests for diabetic kidney disease, endometriosis, and esophageal cancer. The company plans to use the funds to establish a US laboratory and pursue FDA accreditation.

Showing 1 to 4 of 4 results